Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

our co-therapy trials in the U.K. and our sarcoma study in the U.S. We believe that the results from these trials will allow us to broaden our Phase II clinical trial program and choose a pivotal trial path. As well, we believe that the NCI will commence enrollment in its two sponsored clinical trials.

We expect to produce REOLYSIN(R) for our clinical trial program throughout 2008. We believe we will complete our 100-litre scale up studies and will continue our examination of a lyophilization (freeze drying) process for REOLYSIN(R).

We continue to estimate, based on our expected activity for 2008 that our average monthly cash usage will be $1,660,000 per month (see "Liquidity and Capital Resources").

Recent 2008 Progress

Clinical Trials - Positive Interim Results

In April, we announced positive interim results and completion of the dose escalation portion of our U.K. combination REOLYSIN(R) and carboplatin/paclitaxel trial. Four of the first eight patients treated in the study to date have a diagnosis of carcinoma of the head and neck. All three head and neck patients evaluated to date have had excellent clinical and radiological responses without appreciable toxicity. Preliminary assessment after recruitment of the first two cohorts has suggested that patients with head and neck carcinomas represent a group of patients for whom the combination of carboplatin/paclitaxel and REOLYSIN(R) may prove effective.

In the first cohort, the patient with head and neck cancer received 8 cycles of treatment (the maximum allowed) and achieved a clinical complete response. In the second cohort, the two patients with head and neck cancers with widespread disseminated disease have each received seven cycles of treatment to date and both have achieved significant partial responses. Two of the three patients, including the patient with the clinical complete response, had previously received cisplatin/5-FU treatment and all three had prev
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... , More sensitive than ... Linear quantitation of mRNA targets , over a 106-fold range ... as 500 fg total RNA 1/20th of a single cell! , Fast, ... 15 min , , ...
... Fluorescence activated cell sorting (FACS) is a , ... individual cells using fluorescent probes that bind specifically to ... commonly used to collect , cells of a given ... , Figure 1.Linear Amplification from 1-1000 Cells. , ...
... Remove >90% of mammalian RNA from , ... Simple procedure takes less than 2 hours , ... with , MICROB Express Bacterial mRNA Purification Kit ... bacterial RNA isolated from host cells , ...
Cached Biology Technology:HIGH SENSITIVITY qRT-PCR 2HIGH SENSITIVITY qRT-PCR 3HIGH SENSITIVITY qRT-PCR 4HIGH SENSITIVITY qRT-PCR 5Cells-to-cDNA II Using FACS Sorted Cells 2Bacterial RNA Isolation From Infected Eukaryotic Hosts 2Bacterial RNA Isolation From Infected Eukaryotic Hosts 3Bacterial RNA Isolation From Infected Eukaryotic Hosts 4Bacterial RNA Isolation From Infected Eukaryotic Hosts 5Bacterial RNA Isolation From Infected Eukaryotic Hosts 6
(Date:4/17/2014)... ideas about domestication derive from Charles Darwin, whose ... animal-breeding practices during the 19th century, a period ... , It is from Darwin that we inherit ... animals from wild species and total human control ... management in this industrial setting has been applied ...
(Date:4/16/2014)... State University researchers have identified a new syndrome called ... and muscle mass with obesity. , "It used to ... better your bones would be because the bones were ... Professor of Nutrition at Florida State. "But, that,s only ...
(Date:4/16/2014)... Nicolas Doucet of the Centre INRSInstitut Armand-Frappier has just received ... in the amount of nearly US$600,000. The 5-year grant is ... called RNases and to explore their biomedical potential in the ... , "Receiving a grant at this level is ...
Breaking Biology News(10 mins):The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2
... U.S. west coast is among the richest ecosystems in the ... a great diversity of marine life. Like coastal regions in ... new study led by scientists at the University of California, ... impacts are highest on marine predators such as whales, seals, ...
... better electronics developed during the last decade, as ... energy storage, and clean water. However, exposure to ... and the environment. As a resource for ... Center for Sustainable Nanotechnology (VTSuN) has joined the ...
... University studying the cause of a rare childhood disease ... new findings may provide clues to understanding more common ... tools to treat them. In today,s online edition ... Hart and Jiali Li in the Department of Cell ...
Cached Biology News:Study maps human impacts on top ocean predators along US west coast 2Study maps human impacts on top ocean predators along US west coast 3Nanomaterials database improved to help consumers, scientists track products 2Nanomaterials database improved to help consumers, scientists track products 3Nanomaterials database improved to help consumers, scientists track products 4Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 2Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 3
...
... inhibition of RNase A-type ribonucleases Product Description: ... nonhuman origin that binds noncovalently and inactivates ... B, and C). It does not interfere ... or CL3. QIAGEN RNase Inhibitor inhibits greater ...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Biology Products: